Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  439,675 results for ""ACTIONS "

Your Filters

Geographic : russia Geographic : united states Filter by : Subject
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021.

  • Authors : Vidyasagar N; Pritzker School of Medicine, The University of Chicago, Chicago, Illinois.; Bunting SR

Subjects: Buprenorphine*/Buprenorphine*/Buprenorphine*/administration & dosage ; Buprenorphine*/Buprenorphine*/Buprenorphine*/supply & distribution ; Buprenorphine*/Buprenorphine*/Buprenorphine*/therapeutic use

  • Source: JAMA [JAMA] 2024 Feb 13; Vol. 331 (6), pp. 524-526.Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited

Record details

Read More Add to Saved list
×
Academic Journal

Associations between stimulant use and return to illicit opioid use following initiation onto medication for opioid use disorder.

  • Authors : Foot C; Department of Medicine, Section of Addiction Medicine, Oregon Health and Science University, Portland, OR, USA.; Korthuis PT

Subjects: Central Nervous System Stimulants*/Central Nervous System Stimulants*/Central Nervous System Stimulants*/adverse effects ; Opioid-Related Disorders*/Opioid-Related Disorders*/Opioid-Related Disorders*/drug therapy ; Opioid-Related Disorders*/Opioid-Related Disorders*/Opioid-Related Disorders*/epidemiology

  • Source: Addiction (Abingdon, England) [Addiction] 2024 Jan; Vol. 119 (1), pp. 149-157. Date of Electronic Publication: 2023 Sep 15.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9304118 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.

  • Authors : Mariani JJ; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, New York, USA.; Department of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.

Subjects: Buprenorphine* ; Opioid-Related Disorders*/Opioid-Related Disorders*/Opioid-Related Disorders*/drug therapy; Humans

  • Source: The American journal on addictions [Am J Addict] 2024 Jan; Vol. 33 (1), pp. 8-14. Date of Electronic Publication: 2023 Nov 08.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9208821 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Retrospective analysis of the biopharmaceutics characteristics of solid oral Modified-Release drug products in approved US FDA NDAs designated as Extended-Release or Delayed-Release formulations.

  • Authors : Ahmed N; U.S. Food and Drug Administration (FDA), United States. Electronic address: .; Ly H

Subjects: Biopharmaceutics* ; Polymers*; United States

  • Source: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2023 Dec; Vol. 193, pp. Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 9109778 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia.

  • Authors : Pesa J; Janssen Scientific Affairs, LLC, Titusville, NJ, USA. Electronic address: .; Liu Z

Subjects: Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/therapeutic use ; Schizophrenia*/Schizophrenia*/Schizophrenia*/drug therapy; Adult

  • Source: Schizophrenia research [Schizophr Res] 2023 Nov; Vol. 261, pp. 170-177. Date of Electronic Publication: 2023 Sep 29.Publisher: Elsevier Science Publisher B. V Country of Publication: Netherlands NLM ID: 8804207 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Use and Cost of Sustained-Release Corticosteroids for Cataract Surgery Under the Medicare Pass-Through Program.

  • Authors : Dai X; The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Chang DF

Subjects: Cataract Extraction*/Cataract Extraction*/Cataract Extraction*/economics ; Cataract*; Aged

  • Source: JAMA ophthalmology [JAMA Ophthalmol] 2023 Sep 01; Vol. 141 (9), pp. 844-851.Publisher: American Medical Association Country of Publication: United States NLM ID: 101589539 Publication Model: Print

Record details

Read More Add to Saved list
×
Academic Journal

Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay.

  • Authors : Patel C; Janssen Scientific Affairs, LLC, Titusville, NJ, USA.; Pilon D

Subjects: Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/therapeutic use ; Schizophrenia*/Schizophrenia*/Schizophrenia*/drug therapy; Adult

  • Source: Current medical research and opinion [Curr Med Res Opin] 2023 Aug; Vol. 39 (8), pp. 1157-1166. Date of Electronic Publication: 2023 Jul 28.Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients.

  • Authors : Childress A; Center for Psychiatry and Behavioral Medicine, Inc, Las Vegas, NV, USA.; Sottile R

Subjects: Attention Deficit Disorder with Hyperactivity*/Attention Deficit Disorder with Hyperactivity*/Attention Deficit Disorder with Hyperactivity*/drug therapy ; Viloxazine*/Viloxazine*/Viloxazine*/therapeutic use ; Methylphenidate*/Methylphenidate*/Methylphenidate*/therapeutic use

  • Source: Expert review of neurotherapeutics [Expert Rev Neurother] 2023 Jul-Dec; Vol. 23 (11), pp. 945-953. Date of Electronic Publication: 2023 Oct 27.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101129944 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Current and future directions of drug delivery for the treatment of mental illnesses.

  • Authors : Brewster PR; Department of Biomedical Engineering, University of Mississippi, University, MS 38677, USA; Department of Chemical Engineering, University of Mississippi, University, MS 38677, USA.

Subjects: Autism Spectrum Disorder* ; Mental Disorders*/Mental Disorders*/Mental Disorders*/drug therapy ; Pharmacy*

  • Source: Advanced drug delivery reviews [Adv Drug Deliv Rev] 2023 Jun; Vol. 197, pp. 114824. Date of Electronic Publication: 2023 Apr 15.Publisher: Elsevier Science Publishers, B.V Country of Publication: Netherlands NLM ID: 8710523 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Editorial & Opinion

Long-Acting Injectable Clozapine Not Available in the United States.

Subjects: Clozapine* ; Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/therapeutic use; Humans

  • Source: American family physician [Am Fam Physician] 2023 Jun; Vol. 107 (6), pp. 568.Publisher: American Academy of General Practice Country of Publication: United States NLM ID: 1272646 Publication Model: Print

Record details

Read More Add to Saved list
×
  • 1-10 of  439,675 results for ""ACTIONS "